Genitourinary Syndrome of Menopause – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of genitourinary syndrome of menopause (GSM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of GSM for each country as well as annualized case counts projected to the national population.
We forecast the epidemiology of GSM patient populations in the major mature pharmaceutical markets covered in this report over 20 years.
Clarivate Epidemiology’s GSM forecast will answer the following question:
- How will demographic trends such as population aging and improving life expectancy affect the epidemiology of GSM over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as a part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following GSM subpopulation:
- Concurrent symptoms.
Note: Coverage may vary by country.
Table of contents
- Genitourinary Syndrome of Menopause - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Total Prevalence of Genitourinary Syndrome of Menopause per 100 Women Aged 45 or Older in 2021 and 2041
- Total Prevalence of Genitourinary Syndrome of Menopause per 100 Women Aged 45 or Older in 2021 and 2041
- Relative Sizes of the Contributing Factors to the Trend in the Total Prevalent Cases of Genitourinary Syndrome of Menopause Over the Next 20 Years
- Relative Sizes of the Contributing Factors to the Trend in the Total Prevalent Cases of Genitourinary Syndrome of Menopause Over the Next 20 Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Julie Davis, M.P.H., Senior Epidemiologist, Epidemiology. Before joining Clarivate, Ms. Davis was a research assistant at Tufts Medical Center, where she studied accelerated osteoarthritis and other rheumatic diseases. She also has experience working with zoonotic disease transmission in Ethiopia and excess mortality in Puerto Rico stemming from Hurricane Maria. She was part of the Health Emergencies team at the Pan American Health Organization, working on disaster preparedness and disease risk assessments. Ms. Davis holds a master’s degree in global health epidemiology and disease control from George Washington University and a B.S. in health sciences from James Madison University.